The Board of Directors of Ipca Laboratories Limited met on May 29, 2026, and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The standalone revenue from operations for the quarter ended March 31, 2026, was Rs. 1,814.35 Crores, compared to Rs. 1,845.18 Crores in the previous quarter and Rs. 1,638.44 Crores in the corresponding quarter of the last year. The standalone profit for the period was Rs. 262.29 Crores for the current quarter, compared to Rs. 303.45 Crores in the previous quarter and a loss of Rs. 65.05 Crores in the corresponding quarter of the last year.

Ipca Laboratories Limited is a fully integrated pharmaceutical company that produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). The company has a strong focus on both domestic and export markets, operating in the pharmaceutical sector.

The company recently announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. Ipca Laboratories reported that its standalone net total income rose by 10% to Rs. 7,431.39 Crores for the financial year 2026. Additionally, the Board has recommended a dividend of Rs. 6/- per share (600%) for the financial year ended March 31, 2026, subject to shareholder approval. The company has also re-appointed Mr. Prashant Godha as an Executive Director for a further period of 5 years effective from August 16, 2026.

For the last quarterly financial result announced, Ipca Laboratories reported a standalone profit after tax before exceptional items of Rs. 292.71 Crores, which marks a 35% growth compared to the same period in the previous year. The company’s standalone EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 25.27% for Q4 FY26, up from 21.19% in Q4 FY25.